Document is current
Any future updates will be listed below
-
Authors
Alves Fernandes, Thaís Antonia
Tourville, Aurore
Ciss, Ismaila
Ribeiro Silva, Rafaela
Andretto de Mattos, Bianca https://orcid.org/0000-0002-6325-1064
dos Santos Pereira, Maurício https://orcid.org/0000-0001-9012-7379
Oblaza, Maxime
Brunel, Jean-Michel https://orcid.org/0000-0002-9355-8980
Ferrié, Laurent https://orcid.org/0000-0002-1171-205X
Raisman-Vozari, Rita https://orcid.org/0000-0003-4873-3935
Figadère, Bruno https://orcid.org/0000-0003-4226-8489
Del-Bel, Elaine https://orcid.org/0000-0002-4158-7376
Michel, Patrick Pierre https://orcid.org/0000-0001-5607-3119
-
Funding
Funding for this research was provided by:
Capes-Cofecub (88887.710933/2022-00; Me 928/19, 88887.710933/2022-00; Me 928/19, 88887.710933/2022-00; Me 928/19)
Institut Carnot (CM157, CM157)
Association France Parkinson
Neuroscience Acceleration Launchpad NeurAL-2023
CNRS's pre-maturation program
CAPES (88887595435/2020-00)
- License Information
-
More Information
Article History
Received: 14 November 2024
Revised: 14 March 2025
Accepted: 17 March 2025
First Online: 22 March 2025
Declarations
:
: P.P.M., R.R-V., E.D.B., L.F., and B.F. have filed patent applications for the treatment of Parkinson’s disease and related disorders using non-antibiotic tetracycline derivatives.
